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INTRODUCTION
Despite the development of ever more efficacious
and safe pharmacological treatments, cardiovascular
diseases are still the leading cause of death and invalid-
ity in the developed countries, and in most of the so
called “second world” (1). Arterial hypertension is one of
the most relevant independent cardiovascular disease
risk factor and recent studies show that the mainte-
nance of normal blood pressure level also in not frankly
hypertensive subjects is associated to a significant re-
duced incidence of cardiovascular events (2). Of
course, it is not plausible to pharmacologically treat all
subjects with normal-high blood pressure and all inter-
national guidelines stress the relevance of an adequate
dietary and life-style intervention in order to reach and
maintain optimal blood pressure levels. Moreover, in our
era of multiple pharmacological treatments for cardio-
vascular diseases, some researchers believe that sim-
ple dietary interventions or nutritional supplements may
be a more natural and acceptable method of providing
benefits, and patients appear very keen to sponta-
neously use different dietary supplements (whose effi-
cacy is not always evident) to reduce their blood pres-
sure, without asking their physicians for information (3).
Both health professionals and the public are increas-
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ingly interested in the supposed role of omega-3
polyunsaturated fatty acids (PUFAs) from fish and fish
oils in the prevention and management of coronary
heart disease (4). 
Moreover, the worldwide use of PUFA supplementa-
tion has recently received a large implementation even
in fields unrelated to cardiovascular diseases, such as
neurology (epilepsies), psychiatry (psychosis, severe
depressions), rheumatology (osteoarthritis, psoriasis),
clinical immunology (allergy), gastroenterology (inflam-
matory bowel diseases), nephrology (autoimmune
nephropathies) (i.e.: chronic renal failure, congestive
heart failure) (5). 
If PUFAs also have a small but significant blood pres-
sure lowering effect, this potential wide use could have
a relevant epidemiological effect on blood pressure at
the population level, because of the high a priori proba-
bility of comorbidity between those conditions and arte-
rial hypertension.
The aim of this review is to critically evaluate the
available information about PUFA effect on blood pres-
sure control and prevention.
Data sources
We searched PubMed and Embase for relevant arti-
cles by using the key words “fish”, “fish oils”, “omega 3
fatty acids”, “polyunsaturated fatty acids”, “PUFA”,
“Eicosapentaenoic acid”, “EPA”, “Docosahexaenoic
acid”, “DHA” and “blood pressure” or “arterial hyper-
tension”, using a combined text word and MESH head-
ing search strategy. Then we cross-matched references
with those found in each paper.
Biochemical classification and food sources
Alpha-linolenic acid (ALA; 18:3 omega-3) together
with linoleic acid (LA; 18:2 omega-6) are essential fatty
acids for humans. LA is the most predominant omega-3
PUFA in our diet, which is commonly found in vegetable
seed oils. ALA is less abundant than LA; ALA is also pre-
sent in some vegetable oils such as perilla, flaxseed,
canola, soybean and walnut oils. Dietary LA is convert-
ed to gamma linolenic acid (GLA, 18:3 omega-6) and di-
homo-GLA (DGLA, 20:3 omega-6) by specific enzymes
(6-desaturase, elongase) that are controlled by genetic
hormonal and nutritional factors. Then, DGLA compete
with alpha-linolenic acid (ALA, 18:3 omega-3) derived
products on the enzyme 5-desaturase for the synthesis
of arachidonic acid or eicosapentaenoic (EPA, 20:5
omega-3). EPA is yet elongated and desaturated to do-
cosahexenoic acid (DHA, 22:6 omega-3) (Fig. 1). Fish
and fish oils are the main dietary sources of EPA and
DHA. The content of EPA and DHA in different kinds of
fish is reported in Table I. Even if less concentrated, EPA
and DHA are also available in some vegetables, such as
corn (and corn oil), lean meat and meat products, offal,
egg yolk, milk and dairy products (5).
Pharmacological aspects
As cycloxigenase (COX) inhibition is often associated
with sodium retention leading to edema and hyperten-
sion (6), prostanoids appear to have a role in preventing
the development of high blood pressure. On the other
TABLE I - MEAN CONTENT OF OMEGA 3 FATTY ACIDS OF 
SELECTED FISH AND SEAFOOD 
FISH  EPA/+DHA content Amount of fish (in g)
(g) per 100 g  required to
serving of fish  provide 1 g
(edible portion)   EPA+/DHA
Tuna (fresh)  0.28-1.51 66-357
Atlantic salmon  1.28-2.15 42.5-70.9
Mackerel 0.4-1.85 54-250
Atlantic herring  2.01 50
Rainbow trout  1.15 87
Sardines 1.15-2 50-87
Halibut 0.47-1.18 85-213
Tuna (canned)  0.31 323
Cod 0.28 357
Haddock 0.24 417
Catfish 0.18 556
Flounder or sole  0.49 204
Oyster 0.44 227
Shrimp 0.32 313
Scallop 0.2 500
Cod liver oil capsule  0.19 5
EPA=eicosapentanoic acid, DHA=docosahexanoic acid. Omega 3
content varies markedly depending on species, season, diet, and
packaging and cooking methods, and the figures above are there-
fore rough estimates.PUFAs and blood pressure
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hand, prostaglandin E2 (PgE2) and PgI2 have also been
implicated as determinants of renin secretion. A recent
study suggests that PgI2 plays a critical role in stimulat-
ing renin release and promoting hypertension following
renal artery stenosis (7).
Patients with uncontrolled essential hypertension
have elevated concentrations of superoxide anion (O2
-*),
hydrogen peroxide (H2O2), lipid peroxides, endothelin,
and transforming growth factor-beta (TGF-beta) with a
simultaneous decrease in endothelial nitric oxide (eNO),
superoxide dismutase (SOD), vitamin E, and long-chain
PUFAs (8). Physiological concentrations of angiotensin
II activate NAD(P)H oxidase and trigger free radical gen-
eration (especially that of O2
-*). Usually, angiotensin II-
induced oxidative stress is abrogated by adequate pro-
duction and release of eNO, which quenches O2
-* to re-
store normotension. Angiotensin II also stimulates the
production of endothelin and TGF-beta. TGF-beta en-
hances NO generation, which in turn suppresses TGF-
beta production (8). Thus, NO has a regulatory role on
TGF- beta production and is also a physiological antag-
onist of endothelin. Antihypertensive drugs suppress
the production of O2
-* and TGF-beta and enhance eNO
synthesis to bring about their beneficial actions (9). 
Omega-3 PUFAs exhibit wide-ranging biological ac-
tions that include regulating both vasomotor tone and
renal sodium excretion, partly competing with omega-6
PUFAs for common metabolic enzymes and thereby de-
creasing the production of prothrombotic and vaso-
costricting rather than vasodilating, antithrombotic, an-
tiaggregatory, and antiinflammatory eicosanoids (10). 
Opposite to saturated and trans-fatty acids, omega-
3 PUFAs contrast the formation of tromboxane A2
(TxA2), a potent vasoconstrictor, and enhance that of
PgI2, a well-known vasodilator. In addition, EPA lowers
tissue levels of arachidonic acid and enhance that of
FGLA, the precursor of PgE1, another vasodilator agent
(10).
PUFAs not only enhance the formation of beneficial
PGs, but also suppress angiotensin-converting enzyme
(ACE) activity, reduce angiotensin II formation, enhance
eNO generation, and suppress TGF-beta expression
(11) (Fig. 2). In experimental animal models it has been
observed that the L-arginine-NO system upregulates
Fig. 1 - Endogenous
metabolism omega-6
and omega-3 polyun-
saturated fatty acids
(PG= prostaglandin,
TX= Thromboxane, LT=
Leukotriene).Borghi and Cicero
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the PUFA metabolism, so that a strict correlation be-
tween PUFA concentration and NO endothelial produc-
tion has been supposed (12). Following control of hy-
pertension with calcium antagonists, beta-blockers,
and ACE inhibitors, the concentration of NO and O2
-* re-
verted to normalcy, whereas those of PUFAs remain low
(13): it opens the possibility of further blood pressure
improvement by PUFA supplementation. The discovery
that PUFA could have a direct blood pressure lowering
effect finally justifies why DHA appears to be as effec-
tive or even slightly more effective than EPA (10), even if
DHA is not a substrate for the cyclooxygenase and
lipoxygenase enzymes involved in eicosanoid metabo-
lism.
Moreover, consumption of breast milk (which is rich
in PUFAs) in perinatal life is associated to a higher PU-
FA tissue content in infants and to a lower insulin-resis-
tance and hypertension rate in adult life, whereas PUFA
deficiency in the perinatal period results in raised blood
pressure later in life (14). The exact mechanism of this
phenomenon has yet to be elucidated, however some
authors have postulated the hypothesis that perinatal
dietary PUFA deficiency could lead to developmental al-
teration of membrane bound receptors related to the
sodium metabolism, such as osmoceptors or an-
giotensin II receptor (14). Patients with essential hyper-
tension and population genetically prone to develop ar-
terial hypertension (15) have low concentrations of vari-
ous PUFAs in their plasma phospholipid fraction. Based
on this, it is proposed that PUFAs serve as endogenous
regulators of ACE activity, O2
-*, eNO generation, and
TGF-beta expression. Further, PUFAs have actions sim-
ilar to statins, inhibit (especially omega-3 PUFAs) cy-
clooxygenase activity and suppress the synthesis of
proinflammatory cytokines, and activate the parasym-
pathetic nervous system, all actions that reduce the risk
of major vascular events. Hence, it is proposed that
availability of adequate amounts of PUFAs during the
critical periods of growth prevents the development of
hypertension in adulthood (15). 
In addition, PUFAs have antinflammatory and en-
dothelial action similar to the so called pleyotropic ef-
fect of the 3-hydroxy-3-Methyl-Glutaryl-Coenzyme A
reductase inhibitors (statins), and also statin use has
been observed to slightly but significantly reduce blood
pressure level both in clinical trial setting and at popula-
tion level (16). 
A recent report suggests that PUFAs could also exert
Fig. 2 - Main pharmacological activ-
ities involved in omega-3 PUFA anti-
hypertensive action.
⇑
⇑ ⇑⇑PUFAs and blood pressure
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their effect on metabolism and hypertension through in-
duction of Cd36 expression whose deficiency underlies
insulin resistance, defective fatty acid metabolism and
hypertriglyceridemia in spontaneously hypertensive
rats (SHRs), and whose expression is modulated
through peroxisome proliferator-activated receptor
(PPAR) transcription factors, by conditions that alter
lipid metabolism such as diabetes mellitus and high-fat
feeding (17).
Always in experimental models, fish oil supplementa-
tion shows to have protective effects on long-term hy-
pertension-related organ damages such as glomerular
enlargement, and glomeruli loss (18).
Clinical data
From an epidemiological point of view, the inverse
association between omega-3 PUFA intake and cardio-
vascular disease morbidity/mortality was established
following the observation that the Greenland Inuit had
low mortality from coronary heart disease despite a diet
that is rich in fat. In the 1970s the Danish investigators
Bang and Dyerberg proposed that this could be be-
cause of the omega-3 PUFA high content in the Inuit 
diet, which consisted largely of fish, seal, and whale
(19). In fact, in these subjects, plasma omega-3 PUFA
concentrations are highly correlated with dietary PUFAs
and inversely correlated with diastolic blood pressure
(20).
Compared with traditional diets, patterns of PUFA in-
take in industrialized nations have shifted markedly dur-
ing the past 150 years toward higher amounts of
omega-6 PUFAs and lower amounts of omega-3 PUFAs,
with parallel increases in coronary heart disease inci-
dence in ecological studies (21).
The inverse correlation between PUFAs intake and
blood pressure could be not true in each ethnicity: for
instance in the Tanzania population it has not been ob-
served (22).
Minimally invasive methods allowed repeat measure-
ments in individuals in whom fish oil supplementation
was tested in the setting of clinical trials. Measurements
have included systemic arterial compliance index, flow-
mediated dilation of the muscular conduit brachial
artery and blood flow in the microcirculation of the fore-
arm and of coronary arteries. Endothelial dysfunction
that partly explains reduced vascular dilatation appears
to predict future adverse coronary heart disease out-
comes. Fish oil supplementation has significantly im-
proved endothelial function measured in terms of nitric
oxide- and flow-mediated dilation and vasodilation of
resistance vessels of the forearm (23). Systemic arterial
compliance index, which reflects distensibility in elastic
proximal large arteries, was equally improved with 3g
DHA (+27%) and 3g EPA (+36%), whereas consumption
of the placebo did not, in a double-blind, parallel de-
sign, placebo-controlled randomized trial (24). Tomiya-
ma et al showed that EPA supplementation (1.8 g/day) is
able to attenuate age-related increase in arterial stiff-
ness in dyslipidemic patients (25). Distensibility of the
common carotid artery has also been shown to improve
with EPA alone. Left ventricular function also improved
in patients taking either EPA or DHA (26). These effects
appear not to be related to alterations in vascular re-
sponses to norepinephrine, angiotensin II or potassium
(27).
In a dietary intervention study, 69 overweight (BMI
>25 kg/m2) medication-treated hypertensive subjects
were randomized to either a daily fish meal (3.65 gr/dL
of omega-3 PUFA approximately), a weight reduction
regimen, the two regimens combined, or a control regi-
men for 16 weeks. Sixty-three subjects completed the
study. Both systolic (SBP) and diastolic (DBP) blood
pressure, body weight and heart rate significantly de-
creased in the fish diet group compared with the con-
trolled diet group, even after adjustment for changes in
urinary sodium, potassium, or the sodium/potassium
ratio, as well as dietary macronutrients. From this data it
could be argued that weight loss in overweight people
can augment the effects of eating fish on ambulatory
24h blood pressure (28).
Then, an observational study was carried out in
which the effects of fish-derived omega-3 PUFA on
blood pressure, platelet fatty acid levels and heart rate
variability (an independent protective factor against
cardiovascular mortality), were investigated in 43 sub-
jects (male 24, female 19, aged 18 to 62 years) with type
1 diabetes mellitus, and 38 subjects (male 24, female
14, aged 37 to 77 years) with type 2 diabetes mellitus
(29). The study found that fish intake was significantly
associated with platelet membrane DHA levels. Accord-
ing to the platelet DHA levels, patients were divided in-
to three tertiles: the first tertile (n = 14) had the lowestBorghi and Cicero
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DHA level, the third tertile (n = 15) the highest DHA lev-
el and the second tertile was in between. Compared
with the first tertile, the third tertile had a significantly
lower DBP. In a further double blind, randomized, place-
bo-controlled human study, it was found that EPA and
DHA differed in their effects on blood pressure and
heart rate (30). In this study, 55 overweight (Body Mass
Index = 25-30 kg/m2) subjects, aged 20-65 years, were
randomized to 4 g/d of purified EPA, DHA, or placebo
(olive oil) capsules for 6 weeks. Compared to the place-
bo group, DHA significantly reduced both SBP and DBP
(measured over 24 hours) by 5.8 and 3.3 mmHg, and the
waking SBP and DBP by 3.5 and 2.0 mmHg, respective-
ly (p<0.05). Compared to the placebo group, heart rate
over a 24-hour period, when awake and when asleep,
was significantly reduced by 3.5 ± 0.8, 3.7 ± 1.2, and 2.8
± 1.2 bpm, respectively. On the other hand, EPA showed
no significant effect on blood pressure and heart rate.
This study has however the limit to not have tested if the
EPA-DHA association has additive or synergic effects
on blood pressure, or not. Authors explain the antihy-
pertensive effect of DHA suggesting that there may be a
significant cardiac component, as demonstrated by the
concomitant reduction in heart rate, possibly mediated
by effects on autonomic nerve function or β-adrenocep-
tor activity.
A meta-analysis of 36 randomised trials, including
the last cited ones, found a mean reduction in SBP of
2.1 mmHg and in DBP of 1.6 mmHg (31), significantly in-
ferior to that reported in some single trials. The main
reason of this low observed effect is that in the meta-
analysis were included also trials where low dosed or
unpurified formulation were used, and where blood
pressure reduction was not a main outcome of the
study. 
Recently, Sanders et al showed that PUFAs extracted
from marine algae (not from fish) had no effects on the
blood pressure levels of seventy-nine patients random-
ized to 4 g/day (providing 1.5 g DHA and 0.6 g DPA) or
placebo in a 4-week double-blind randomized trial (32). 
In normotensive adults, PUFA supplementation ap-
pears not to have significant effect on blood pressure
values if compared to saturated and monounsaturated
fatty acids (33). However, 5 mL fish oil supplementation
is significantly associated to lower SBP levels (-6.3
mmHg 95% CI 0.9, 11.7; p = 0.02) in children taking
them mixed in milk-formulation for one year, as com-
pared with control children (34).
Further clinical research is needed to evaluate the re-
al antihypertensive effect of EPA and DHA, their differ-
ential effects, and to identify a priori the best respon-
ders or candidates for that treatment.
Of course, any recommendations regarding fish and
fish oils should be balanced against safety issues. Side
effects such as fishy aftertaste are uncommon, and gas-
trointestinal upset is infrequent at moderate intakes (4).
Some reports show that fish oil may worsen glycemic
control in diabetes, but a recent meta-analysis excludes
this adverse effect (35). Concerns have been raised re-
garding adverse effects on low density lipoprotein (LDL)
cholesterol and oxidative stress, but increases in LDL
cholesterol are modest and studies about oxidative
stress have been contradictory. Overall these effects
are unlikely to be dominant given the apparent cardiac
benefits of omega-3 PUFAs (36). More specific con-
cerns regarding dietary fish relate to environmental con-
taminants, and a recent study showed that mercury in
fish may attenuate their cardioprotective effects (37).
Contaminants accumulate in larger, predatory fish, and
consumption of a variety of fish should minimise any
possible adverse effects (4).
No significant negative interaction has been ob-
served until now between antihypertensive therapy and
fish oil supplementation.
CONCLUSION
Preliminary data suggest that an adequate PUFA di-
etary intake or supplementation (2-4 g/day) could
slightly but significantly reduce systolic and diastolic
blood pressure level and prevent blood pressure in-
crease in either dyslipidemic, diabetics, elderly, nor-
motensive and hypertensive subjects, contributing to
their cardiovascular protective role. Present and future
research will identify which categories of subjects will
more significantly benefit form PUFA supplementation
in order to maintain adequate levels of blood pressure.
Some research lines are trying to clarify which specif-
ic sub-categories of subjects at cardiovascular risk
could obtain the maximal benefit from an EPA/DHA sup-
plementation and which is the most cost-effective
dosage and EPA/DHA ratio to be employed. In the spe-
cific context of blood pressure management it is proba-PUFAs and blood pressure
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ble that the on-going Gissi-Heart Failure Study, de-
signed to evaluate the effect of EPA/DHA supplementa-
tion or statin treatment on the prognosis of patients af-
fected by chronic heart failure, could furnish relevant
data as it regards the blood pressure control in both
groups of treatment. Because of the specific mecha-
nism of action of PUFA it could be also interesting to
study if PUFA could improve the antihypertensive action
of specific blood pressure lowering drug classes and of
statins. Future guidelines for hypertension management
may suggest to increase the nutritional intake of
EPA/DHA or to supplement it in order to prevent blood
pressure increases or improve the blood pressure con-
trol, especially in subjects that could have special ben-
efit for other concomitant pathologies (e.g. dyslipi-
demias, rheumatological disorders, and perhaps chron-
ic heart failure and chronic renal failure).
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